Clinical trialNCT00049127CompletedPhase 1/PHASE2Interventional

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

SponsorAlliance for Clinical Trials in OncologyEnrollment64Adult Anaplastic OligodendrogliomaAdult Mixed GliomaAdult OligodendrogliomaRecurrent Adult Brain Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kurt Jaeckle, MD
Mayo
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

229 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Saint Francis Hospital and Medical Center
Hartford, Connecticut, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Rush - Copley Medical Center
Aurora, Illinois, United States
Bromenn Lifecare Center
Bloomington, Illinois, United States
Saint Joseph Medical Center
Bloomington, Illinois, United States
Graham Hospital Association
Canton, Illinois, United States
Memorial Hospital
Carthage, Illinois, United States
Eureka Hospital
Eureka, Illinois, United States
Galesburg Cottage Hospital
Galesburg, Illinois, United States
Illinois Cancercare Galesburg
Galesburg, Illinois, United States
Western Illinois Cancer Treatment Center
Galesburg, Illinois, United States
Mason District Hospital
Havana, Illinois, United States
Hopedale Medical Complex - Hospital
Hopedale, Illinois, United States
Joliet Oncology-Hematology Associates Limited
Joliet, Illinois, United States
Kewanee Hospital
Kewanee, Illinois, United States
Mcdonough District Hospital
Macomb, Illinois, United States
Garneau, Stewart C Md (uia Investigator)
Moline, Illinois, United States
Porubcin, Michael Md (uia Investigator)
Moline, Illinois, United States
Sharis, Christine M Md (uia Investigator)
Moline, Illinois, United States
Stoffel, Thomas J Md (uia Investigator)
Moline, Illinois, United States
Vigliotti, Antonio, P.G. M.D. (uia Investigator)
Moline, Illinois, United States
Bromenn Regional Medical Center
Normal, Illinois, United States
Community Cancer Center Foundation
Normal, Illinois, United States
Illinois Cancercare-Ottawa Clinic
Ottawa, Illinois, United States
Ottawa Regional Hospital and Healthcare Center
Ottawa, Illinois, United States
Pekin Cancer Treatment Center
Pekin, Illinois, United States
Pekin Hospital
Pekin, Illinois, United States
Illinois Cancercare-Peoria
Peoria, Illinois, United States
Illinois Oncology Research Association Ccop
Peoria, Illinois, United States
Methodist Medical Center of Illinois
Peoria, Illinois, United States
Osf Saint Francis Medical Center
Peoria, Illinois, United States
Proctor Hospital
Peoria, Illinois, United States
Illinois Valley Hospital
Peru, Illinois, United States
Valley Radiation Oncology
Peru, Illinois, United States
Perry Memorial Hospital
Princeton, Illinois, United States
Sarah Culbertson Memorial Hospital
Rushville, Illinois, United States
Saint Margaret'S Hospital
Spring Valley, Illinois, United States
Carle Cancer Center
Urbana, Illinois, United States
Carle Clinic-Urbana Main
Urbana, Illinois, United States

189 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Imatinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2003
Primary completion: 31 Aug 2011
Completion: 1 Sept 2019
Last update posted: 21 Oct 2019
Registered enrollment: 64
Registry id: NCT00049127

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.